FDA Warns Of High Mortality Rate For Medtronic Stent

Law360, New York (March 19, 2008, 12:00 AM EDT) -- Patients using Medtronic Inc.'s AneuRx stent graft system have a higher mortality rate than previously thought, the U.S. Food and Drug Administration announced this week.

In a statement posted on its Web site, the FDA wrote that the per-year mortality risk in patients receiving the stent continues to increase for years after the device is implanted.

The mortality rate is also significantly higher for patients who have the stent than for patients who have surgery, the FDA said.

Earlier research had suggested that aneurysm-related mortality was...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.